基于多参数磁共振成像的PI-RADS第二版评分联合f/t PSA及PSAD在前列腺癌早期筛查中的预测价值

doi:10.3969/j.issn.1009-976X.2021.02.017

摘要/Abstract

摘要： 目的探讨基于多参数磁共振成像的PI-RADS第二版评分联合f/t PSA及PSAD在前列腺癌早期筛查中的预测价值。方法回顾性分析2015年1月至2020年12月期间的289例疑似前列腺癌患者的临床资料,根据是否确诊前列腺癌分为前列腺癌组和非前列腺癌组,绘制患者PI-RADS第二版评分、f/tPSA及PSAD三项诊断指标的受试者工作特征曲线,并计算曲线下面积（AUC）,分析三个诊断指标以及联合指标对PCa的灵敏度和特异度。结果一致性检验显示Kappa系数为0.798,说明两名医师的评分结果具有高度一致性。289例前列腺癌患者中,PCa组及非PCa组患者在PI-RADS第二版评分、f/t PSA及PSAD三项诊断指标的差异均有统计学意义。f/t PSA、PI-RADS第二版评分、PSAD三项诊断指标以及联合指标的AUC分别为0.633、0.796、0.785和0.908（P<0.001）。结论基于多参数磁共振成像的PI-RADS第二版评分联合f/t PSA及PSAD可作为前列腺癌早期筛查的客观指标。

关键词: 多参数磁共振成像, PI-RADS第二版评分, 前列腺癌, f/tPSA, 前列腺特异性抗原密度

Abstract: Objective To investigate the predictive value of PI-RADS V2 based on multi-parameter magnetic resonance imaging combined with f/t PSA and PSAD in prostate cancer. Methods All the clinical data of 289 patients with suspected prostate cancer were analyzed in the hospital of Yangchun city from January 2015 to December 2020, retrospectively. 123 patients with prostate cancer （PCa） were selected as PCa group, and 166 cases without PCa were selected as Non-PCa group. The receiver operator characteristic curve were performed to verify the diagnostic value of PI-RADS v2, the f/t PSA and PSAD, and the area under curve （AUC） were calculated. The sensitivity and specificity of the prostate cancer were analyzed by three diagnostic indicators and joint indicators. Results The consistency test between two groups showed that Kappa coefficient was 0.798, which indicated that the scoring results of the two physicians were highly consistent. The AUC of the diagnostic indexes of PI-RADS v2, f/t PSA, PSAD and the combined indexes were 0.633, 0.796, 0.785 and 0.908, respectively.The difference was statistically significant. Conclusion PI-RADS v2 combined with f/t PSA and PSAD can be used as Objective indicators for the early diagnosis of prostate cancer, and it is worthy of promotion.

Key words: prostate cancer, PI-RADS v2, multi-parameter magnetic resonance imaging, f/t PSA, PSAD

中图分类号:

陈秀凤, 卜庆丰, 张杰. 基于多参数磁共振成像的PI-RADS第二版评分联合f/t PSA及PSAD在前列腺癌早期筛查中的预测价值[J]. 岭南现代临床外科, 2021, 21(02): 213-216.

CHEN Xiu-feng, BU Qing-feng, ZHANG Jie. The predictive value of PI-RADS v2 based on multi-parameter magnetic resonance imaging combined with f/t PSA and PSAD in prostate cancer[J]. Lingnan Modern Clinics In Surgery, 2021, 21(02): 213-216.

参考文献

[1] 那彦群, 叶章群, 孙光, 主编. 中国泌尿外科疾病诊断治疗指南[M]. 北京:人民卫生出版社, 2014: 62-89.
[2] Flores-Fraile MC, Padilla-Fernández BY, Valverde-Martínez S, et al.The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions[J]. J Clin Med, 2020, 9(11):3400.
[3] Javaeed A, Ghauri SK, Ibrahim A, et al.Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer-a systematic review[J]. Oncol Rev, 2020, 14(1): 449.
[4] Yusim I, Krenawi M, Mazor E, et al.The use of prostate specific antigen density to predict clinically significant prostate cancer[J]. Sci Rep, 2020, 10(1): 20015.
[5] Lim B, Choi SY, Kyung YS, et al.Value of clinical parameters and MRI with PI-RADSV2 in predicting seminal vesicle invasion of prostate cancer[J]. Scand J Urol, 2020, 21(1):17-21.
[6] Weinreb JC, Barentsz JO, Choyke PL, et al.PI-RADS Prostate Imaging-Reporting and Data System: 2015, Version 2[J]. Eur Urol, 2015, 69(1):16-40.
[7] 赵耀瑞, 徐勇, 张殿举,等. 血清PSA、 PSAD和PSAT在前列腺穿刺活检中的意义[J].中华泌尿外科杂志, 2005, 26(9):622-625.
[8] 杨硕,张跃跃,赵文露,等. 前列腺特异性抗原及其衍生指标在第二版前列腺影像报告与数据系统3分病灶临床决策中的价值[J]. 中华医学杂志,2020, 100(13):997-1001.
[9] Viana PCC, Horvat N, do Santos VR Júnior, et al. Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?[J]. Int Braz J Urol, 2019, 45(4): 724-731.
[10] Lu YF, Zhang Q, Yao WG, et al.Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data[J]. Cancer Imaging, 2019, 19(1):26.
[11] Zhu Y, Han CT, Zhang GM, et al.Development and external validation of a prostate health index-based nomogram for predicting prostate cancer[J]. Sci Rep, 2015, 5:15341.
[12] Ding Z, Wu H, Song D, et al.Development and validation of a nomogram for predicting prostate cancer in men with prostate-specific antigen grey zone based on retrospective analysis of clinical and multi-parameter magnetic resonance imaging/ transrectal ultrasound fusion-derived data[J]. Transl Androl Urol, 2020, 9(5): 2179-2191.
[13] 雷李智,许乙凯,侯美蓉,等. 前列腺影像报告和数据系统联合前列腺特异性抗原的Logistic回归模型评价外周带前列腺癌的诊断效能[J]. 南方医科大学学报,2017,37(8):1092-1097.

[1]	袁红, 胡小芳, 陈业辉, 李淑霞. 基于微视频健康教育在前列腺癌根治术后留置尿管患者护理中的初步观察[J]. 岭南现代临床外科, 2020, 20(05): 677-680.
[2]	陈美贤, 杨雪莹, 廖朝霞, 叶西就, 陆福鼎. “深肌松”在肥胖患者行机器人辅助腹腔镜下根治性前列腺癌切除术中的应用观察[J]. 岭南现代临床外科, 2020, 20(04): 468-471.
[3]	袁小旭, 邱剑光, 朱雨沫, 林雪花, 庞国福, 邓建, 谢群. 经会阴前列腺穿刺与经直肠前列腺穿刺活检在前列腺癌诊断的初探[J]. 岭南现代临床外科, 2020, 20(04): 484-487.
[4]	胡丽娟，戴奇山，胡建波*. 89锶、唑来膦酸及99锝-亚甲基二膦酸盐治疗老年前列腺癌骨转移的临床观察[J]. 岭南现代临床外科, 2019, 19(04): 437-446.
[5]	胡丽娟，戴奇山，胡建波*. 阿比特龙联合泼尼松治疗老年转移性去势抵抗前列腺癌的临床观察[J]. 岭南现代临床外科, 2019, 19(03): 333-336.
[6]	尤洪科1，文博1，尹永华1. 去泛素化酶3在前列腺癌中的表达及其对前列腺癌细胞生物学特性的影响[J]. 岭南现代临床外科, 2019, 19(03): 337-340.
[7]	叶秀钦，丁志敏，董发进，魏章洪，刘慧玉，吴淮宇，徐金锋*. 经直肠实时弹性成像引导靶向穿刺在前列腺病变的应用价值研究[J]. 岭南现代临床外科, 2019, 19(02): 195-198.
[8]	林春浩，赖义明，彭圣萌，黄海，郭正辉. Polo样激酶3在前列腺癌中的表达及临床意义[J]. 岭南现代临床外科, 2018, 18(02): 133-136.
[9]	韦兴华林煜荣杨文俊谢克基汤平. PSA密度在PSA 2.5~10.0 ng/mL和10.1~20.0 ng/mL患者前列腺癌诊断价值的多中心研究[J]. 岭南现代临床外科, 2016, 16(03): 327-330.
[10]	萧聪勤胡建波周一南. 染料木黄酮诱导前列腺癌DU-145细胞凋亡的研究[J]. 岭南现代临床外科, 2016, 16(02): 215-218.
[11]	万跃平习明万颂华伟曾昭昌刘远灵林卓远吴永定杨盛帮韩兆冬. 前列腺癌组织中TRIB1基因和蛋白异常表达与患者不良预后的相关性[J]. 岭南现代临床外科, 2016, 16(01): 87-91.
[12]	汤永峰陈果蔡志锻李博伟叶剑恒吴永定周亮钟惟德韩兆冬. IMPDH2蛋白与前列腺癌临床相关性分析[J]. 岭南现代临床外科, 2015, 15(04): 490-493.
[13]	刘毅豪. 不同PSA相关肿瘤标志物在前列腺癌中的诊断价值[J]. 岭南现代临床外科, 2015, 15(04): 494-497.
[14]	徐文锋余定宇张友強陈雁如黄亚强陈佳鸿何慧婵钟惟德江福能. MYL9在间质中的表达下调与前列腺癌患者的不良临床预后[J]. 岭南现代临床外科, 2014, 14(04): 358-361.
[15]	蔡海鹏李清荣. 手术前后前列腺癌患者自然杀伤T细胞的变化及意义[J]. 岭南现代临床外科, 2014, 14(04): 411-413.